Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
CANCER:
Peritoneal Cancer
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Associations
(91)
News
Trials
VERI cancer hierarchy
Reset Filters
No biomarker
Peritoneal Cancer
No biomarker
Peritoneal Cancer
niraparib
Sensitive: A1 - Approval
niraparib
Sensitive
:
A1
niraparib
Sensitive: A1 - Approval
niraparib
Sensitive
:
A1
BRCA1 mutation
Peritoneal Cancer
BRCA1 mutation
Peritoneal Cancer
bevacizumab + olaparib
Sensitive: A1 - Approval
bevacizumab + olaparib
Sensitive
:
A1
bevacizumab + olaparib
Sensitive: A1 - Approval
bevacizumab + olaparib
Sensitive
:
A1
No biomarker
Peritoneal Cancer
No biomarker
Peritoneal Cancer
bevacizumab
Sensitive: A1 - Approval
bevacizumab
Sensitive
:
A1
bevacizumab
Sensitive: A1 - Approval
bevacizumab
Sensitive
:
A1
No biomarker
Peritoneal Cancer
No biomarker
Peritoneal Cancer
rucaparib
Sensitive: A1 - Approval
rucaparib
Sensitive
:
A1
rucaparib
Sensitive: A1 - Approval
rucaparib
Sensitive
:
A1
No biomarker
Peritoneal Cancer
No biomarker
Peritoneal Cancer
olaparib
Sensitive: A1 - Approval
olaparib
Sensitive
:
A1
olaparib
Sensitive: A1 - Approval
olaparib
Sensitive
:
A1
No biomarker
Peritoneal Cancer
No biomarker
Peritoneal Cancer
bevacizumab-awwb
Sensitive: A1 - Approval
bevacizumab-awwb
Sensitive
:
A1
bevacizumab-awwb
Sensitive: A1 - Approval
bevacizumab-awwb
Sensitive
:
A1
No biomarker
Peritoneal Cancer
No biomarker
Peritoneal Cancer
Aybintio (bevacizumab biosimilar)
Sensitive: A1 - Approval
Aybintio (bevacizumab biosimilar)
Sensitive
:
A1
Aybintio (bevacizumab biosimilar)
Sensitive: A1 - Approval
Aybintio (bevacizumab biosimilar)
Sensitive
:
A1
No biomarker
Peritoneal Cancer
No biomarker
Peritoneal Cancer
Aybintio (bevacizumab biosimilar)
Sensitive: A1 - Approval
Aybintio (bevacizumab biosimilar)
Sensitive
:
A1
Aybintio (bevacizumab biosimilar)
Sensitive: A1 - Approval
Aybintio (bevacizumab biosimilar)
Sensitive
:
A1
BRCA1 mutation
Peritoneal Cancer
BRCA1 mutation
Peritoneal Cancer
rucaparib
Sensitive: A1 - Approval
rucaparib
Sensitive
:
A1
rucaparib
Sensitive: A1 - Approval
rucaparib
Sensitive
:
A1
BRCA2 mutation
Peritoneal Cancer
BRCA2 mutation
Peritoneal Cancer
rucaparib
Sensitive: A1 - Approval
rucaparib
Sensitive
:
A1
rucaparib
Sensitive: A1 - Approval
rucaparib
Sensitive
:
A1
BRCA2 mutation
Peritoneal Cancer
BRCA2 mutation
Peritoneal Cancer
bevacizumab + olaparib
Sensitive: A1 - Approval
bevacizumab + olaparib
Sensitive
:
A1
bevacizumab + olaparib
Sensitive: A1 - Approval
bevacizumab + olaparib
Sensitive
:
A1
HRD
Peritoneal Cancer
HRD
Peritoneal Cancer
bevacizumab + olaparib
Sensitive: A1 - Approval
bevacizumab + olaparib
Sensitive
:
A1
bevacizumab + olaparib
Sensitive: A1 - Approval
bevacizumab + olaparib
Sensitive
:
A1
BRCA1 mutation
Peritoneal Cancer
BRCA1 mutation
Peritoneal Cancer
niraparib
Sensitive: A1 - Approval
niraparib
Sensitive
:
A1
niraparib
Sensitive: A1 - Approval
niraparib
Sensitive
:
A1
BRCA2 mutation
Peritoneal Cancer
BRCA2 mutation
Peritoneal Cancer
niraparib
Sensitive: A1 - Approval
niraparib
Sensitive
:
A1
niraparib
Sensitive: A1 - Approval
niraparib
Sensitive
:
A1
HRD
Peritoneal Cancer
HRD
Peritoneal Cancer
niraparib
Sensitive: A1 - Approval
niraparib
Sensitive
:
A1
niraparib
Sensitive: A1 - Approval
niraparib
Sensitive
:
A1
BRCA2 mutation
Peritoneal Cancer
BRCA2 mutation
Peritoneal Cancer
olaparib
Sensitive: A1 - Approval
olaparib
Sensitive
:
A1
olaparib
Sensitive: A1 - Approval
olaparib
Sensitive
:
A1
BRCA1 mutation
Peritoneal Cancer
BRCA1 mutation
Peritoneal Cancer
olaparib
Sensitive: A1 - Approval
olaparib
Sensitive
:
A1
olaparib
Sensitive: A1 - Approval
olaparib
Sensitive
:
A1
No biomarker
Peritoneal Cancer
No biomarker
Peritoneal Cancer
carboplatin + micellar paclitaxel
Sensitive: A1 - Approval
carboplatin + micellar paclitaxel
Sensitive
:
A1
carboplatin + micellar paclitaxel
Sensitive: A1 - Approval
carboplatin + micellar paclitaxel
Sensitive
:
A1
No biomarker
Peritoneal Cancer
No biomarker
Peritoneal Cancer
bevacizumab-maly
Sensitive: A1 - Approval
bevacizumab-maly
Sensitive
:
A1
bevacizumab-maly
Sensitive: A1 - Approval
bevacizumab-maly
Sensitive
:
A1
BRCA2 mutation
Peritoneal Cancer
BRCA2 mutation
Peritoneal Cancer
pamiparib
Sensitive: A1 - Approval
pamiparib
Sensitive
:
A1
pamiparib
Sensitive: A1 - Approval
pamiparib
Sensitive
:
A1
BRCA1 mutation
Peritoneal Cancer
BRCA1 mutation
Peritoneal Cancer
pamiparib
Sensitive: A1 - Approval
pamiparib
Sensitive
:
A1
pamiparib
Sensitive: A1 - Approval
pamiparib
Sensitive
:
A1
No biomarker
Peritoneal Cancer
No biomarker
Peritoneal Cancer
bevacizumab-adcd
Sensitive: A1 - Approval
bevacizumab-adcd
Sensitive
:
A1
bevacizumab-adcd
Sensitive: A1 - Approval
bevacizumab-adcd
Sensitive
:
A1
FOLR1 positive
Peritoneal Cancer
FOLR1 positive
Peritoneal Cancer
mirvetuximab soravtansine-gynx
Sensitive: A1 - Approval
mirvetuximab soravtansine-gynx
Sensitive
:
A1
mirvetuximab soravtansine-gynx
Sensitive: A1 - Approval
mirvetuximab soravtansine-gynx
Sensitive
:
A1
No biomarker
Peritoneal Cancer
No biomarker
Peritoneal Cancer
bevacizumab-tnjn
Sensitive: A1 - Approval
bevacizumab-tnjn
Sensitive
:
A1
bevacizumab-tnjn
Sensitive: A1 - Approval
bevacizumab-tnjn
Sensitive
:
A1
MSI-H/dMMR
Peritoneal Cancer
MSI-H/dMMR
Peritoneal Cancer
pembrolizumab
Sensitive: A2 - Guideline
pembrolizumab
Sensitive
:
A2
pembrolizumab
Sensitive: A2 - Guideline
pembrolizumab
Sensitive
:
A2
No biomarker
Peritoneal Cancer
No biomarker
Peritoneal Cancer
BEP
Sensitive: A2 - Guideline
BEP
Sensitive
:
A2
BEP
Sensitive: A2 - Guideline
BEP
Sensitive
:
A2
TMB-H
Peritoneal Cancer
TMB-H
Peritoneal Cancer
pembrolizumab
Sensitive: A2 - Guideline
pembrolizumab
Sensitive
:
A2
pembrolizumab
Sensitive: A2 - Guideline
pembrolizumab
Sensitive
:
A2
No biomarker
Peritoneal Cancer
No biomarker
Peritoneal Cancer
EP
Sensitive: A2 - Guideline
EP
Sensitive
:
A2
EP
Sensitive: A2 - Guideline
EP
Sensitive
:
A2
No biomarker
Peritoneal Cancer
No biomarker
Peritoneal Cancer
VAC
Sensitive: A2 - Guideline
VAC
Sensitive
:
A2
VAC
Sensitive: A2 - Guideline
VAC
Sensitive
:
A2
No biomarker
Peritoneal Cancer
No biomarker
Peritoneal Cancer
IP
Sensitive: A2 - Guideline
IP
Sensitive
:
A2
IP
Sensitive: A2 - Guideline
IP
Sensitive
:
A2
No biomarker
Peritoneal Cancer
No biomarker
Peritoneal Cancer
FOLFOX
Sensitive: A2 - Guideline
FOLFOX
Sensitive
:
A2
FOLFOX
Sensitive: A2 - Guideline
FOLFOX
Sensitive
:
A2
No biomarker
Peritoneal Cancer
No biomarker
Peritoneal Cancer
CAPOX
Sensitive: A2 - Guideline
CAPOX
Sensitive
:
A2
CAPOX
Sensitive: A2 - Guideline
CAPOX
Sensitive
:
A2
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login